ClinicalTrials.gg

Program

pocenbrodib

Also written as “Pocenbrodib”, “Pocenbrodib and Darolutamide” and “FT-7051”.

Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Sep 24, 20202 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk10 open or runningphase 1since Sep 24, 2020Sep 24, 2020none ahead
Pathos AI11 open or runningphase 2since Dec 10, 2024Dec 10, 2024Jun 30, 2028phase 2 · NCT06785636

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 24, 2020First study: phase 1 study in Prostatic NeoplasmsNew to Novo NordiskNovo Nordisk · NCT04575766 · 25 enrolled · United States
  2. Dec 10, 2024Pathos AI’s first study: phase 2 study in Prostatic NeoplasmsNew to Pathos AIPathos AI · NCT06785636 · 120 planned · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Prostatic NeoplasmsPathos AI · NCT06785636

TargetBeta

OPN1LW →read by rule
“An orally bioavailable inhibitor of the bromodomain of the histone acetyltransferase (HAT) paralogs, CREB binding protein (CBP) and p300 (E1A-associated protein p300; p300 HAT), ”NCIt, by rule

Other programs on OPN1LW

ProgramCompanyFurthest phaseStudies
inobrodibrulecellcentric-ltdphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06785636Prostatic Neoplasms · United States2RecruitingPathos AIJun 30, 2028120
NCT04575766Prostatic Neoplasms · United States1TerminatedNovo NordiskNov 8, 202225

How it is read

Names in the registry

  • “Pocenbrodib”, 1 entry
  • “Pocenbrodib and Darolutamide”, 1 entry
  • “FT-7051”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.